Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - REFLECT SCIENTIFIC INCFinancial_Report.xls
EX-31 - 302 CERTIFICATION OF KIM BOYCE - REFLECT SCIENTIFIC INCex311.htm
EX-32 - 906 CERTIFICATION - REFLECT SCIENTIFIC INCex32.htm
EX-31 - 302 CERTIFICATION OF KEITH MERRELL - REFLECT SCIENTIFIC INCex312.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended September 30, 2014


or


[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT of 1934


For the transition period from __________ to __________


Commission File Number 000-31377


REFLECT SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)


Utah

87-0642556

(State or other jurisdiction of

(IRS Employer Identification No.)

incorporation or organization)


1266 South 1380 West Orem, Utah 84058

 (Address of principal executive offices) (Zip Code)


(801) 226-4100

 (Registrant’s telephone number, including area code)


Indicate by check mark whether the Registrant:  (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]   No [   ]


Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.  See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.  (Check one):


Large Accelerated filer   ¨

Accelerated filer                    ¨

Non-accelerated filer      ¨

Smaller reporting company   x


Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]   No [X]


Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).  

Yes [ X ]   No [  ]


Applicable Only to Issuers Involved in Bankruptcy Proceedings During the Preceding Five Years:


Indicate by check mark whether the Registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.


Not applicable.



1






Applicable Only to Corporate Issuers:


Indicate the number of shares outstanding of each of the Registrant’s classes of common equity, as of the latest practicable date.


Class

Outstanding as of November 10, 2014



53,726,967 shares of $0.01 par value common stock on November 10, 2014






2





TABLE OF CONTENTS


PART I – FINANCIAL INFORMATION


Item 1:  Financial Statements


Condensed Consolidated Balance Sheets

As of September 30, 2014, and December 31, 2013

  

              5


Condensed Consolidated Statements of Operations

For the three and nine months ended September 30, 2014 and 2013    

  7


Condensed Consolidated Statements of Cash Flows

For the nine months ended September 30, 2014 and 2013

   

         

  8


Notes to the Condensed Consolidated Financial Statements

  9


Item 2:  Management’s Discussion and Analysis of Financial Condition and Results of Operations

11


Item 3:  Quantitative and Qualitative Disclosure about Market Risk

15


Item 4:  Controls and Procedures

15


PART II – OTHER INFORMATION


Item 1:  Legal Proceedings

15


Item 2:  Unregistered Sales of Equity Securities and Use of Proceeds

15


Item 3:

Defaults Upon Senior Securities

16


Item 4:  Mine Safety Disclosure

16


Item 5:  Other Information

16


Item 6:  Exhibits

16


Signatures

18



















3







Part I - FINANCIAL INFORMATION


Item 1.  Financial Statements

Reflect Scientific, Inc.


CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

September 30, 2014


The financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.  However, in the opinion of management, all adjustments (which include only normal recurring accruals) necessary to present fairly the financial position and results of operations for the periods presented have been made.  These financial statements should be read in conjunction with the accompanying notes, and with the historical financial information of the Company.









































 

4




REFLECT SCIENTIFIC, INC.


Condensed Consolidated Balance Sheets

(Unaudited)


ASSETS



 

 

September 30,

2014

 

December 31,

2013

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

 

 

 

 Cash

$

         328,785

$

251,463

 Accounts receivable, net

 

           127,262

 

152,583

 Inventories

 

         297,837

 

313,092

 Prepaid assets

 

           3,100

 

3,100

 

 

 

 

 

Total Current Assets

 

         756,984

 

720,238

 

 

 

 

 

FIXED ASSETS, NET

 

          223

 

1,226

 

 

 

 

 

OTHER ASSETS

 

 

 

 

 

 

 

 

 

   Intangible assets, net

 

         43,828

 

73,184

   Goodwill

 

60,000

 

60,000

   Deposits

 

3,100

 

3,100

 

 

 

 

 

      Total Other Assets

 

         106,928

 

136,284

 

 

 

 

 

   TOTAL ASSETS

$

         864,135

$

857,748



















The accompanying notes are an integral part of these condensed consolidated financial statements.




5





REFLECT SCIENTIFIC, INC.

Condensed Consolidated Balance Sheets (Continued)

(Unaudited)



LIABILITIES AND SHAREHOLDERS’ DEFICIT



 

 

September 30,

2014

 

December 31,

2013

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

  Accounts payable

$

          43,272

$

          43,430

  Short-term lines of credit

 

           22,932

 

30,526

  Convertible debenture

 

         650,000

 

         650,000

  Interest payable

 

617,625

 

529,875

  Customer deposits

 

1,953

 

1,060

  Accrued expenses

 

 5,202

 

22,116

  Loan from related party

 

           80,000

 

80,000

  Income taxes payable

 

100

 

100

 

 

 

 

 

      Total Current Liabilities

 

         1,421,084

 

         1,357,107

 

 

 

 

 

      Total Liabilities

 

1,421,084

 

1,357,107

 

 

 

 

 

SHAREHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

 

   Preferred stock, $0.01 par value, authorized

    5,000,000 shares; No shares issued and outstanding

 


-

 


-

   Common stock, $0.01 par value, authorized

    100,000,000 shares; 53,726,967 and 53,726,967

        issued and outstanding, respectively

 

           537,269

 

           537,269

   Additional paid in capital

 

       18,391,300

 

       18,391,300

   Accumulated deficit

 

       (19,485,518)

 

       (19,427,928)

 

 

 

 

 

      Total Shareholders’ Deficit

 

         (556,949)

 

         (499,359)

 

 

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT


$


        864,135


$


         857,748











The accompanying notes are an integral part of these condensed consolidated financial statements.



6





REFLECT SCIENTIFIC, INC.

Condensed Consolidated Statements of Operations

(Unaudited)


 

For the Three Months Ended

September 30,

 

For the Nine Months Ended

September 30,

 

 

2014

 

2013

 

2014

 

2013

REVENUES

$

       290,711

$

        389,562


$

       1,072,066


$

        954,527

 

 

 

 

 

 

 

 

 

COST OF GOODS SOLD

 

116,264

 

181,931

 

447,513

 

448,923

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

174,447

 

207,631

 

624,553

 

505,604

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

   Salaries and wages

 

105,674

 

100,445

 

306,711

 

289,722

   Rent expense

 

8,483

 

9,412

 

25,733

 

28,236

   Research and development expense

 

15,145

 

12,009

 

26,562

 

29,176

   General and administrative expense

 

78,615

 

100,755

 

230,965

 

318,806

      Total Operating Expenses

 

207,917

 

222,621

 

589,971

 

665,940

 

 

 

 

 

 

 

 

 

OPERATING PROFIT (LOSS)

 

(33,470)

 

(14,990)

 

34,582

 

(160,336)

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

  Other income

 

152

 

710

 

964

 

2,880

  Interest expense – other

 

(1,754)

 

(1,919)

 

(5,386)

 

(5,820)

  Interest on debentures

 

(29,250)

 

(29,250)

 

(87,750)

 

(81,000)

 

 

 

 

 

 

 

 

 

      Total Other Income (Expenses)

 

(30,852)

 

(30,459)

 

(92,172)

 

(83,940)

 

 

 

 

 

 

 

 

 

NET LOSS BEFORE TAXES

 

(64,322)

 

(45,449)

 

(57,590)

 

(244,276)

 

 

 

 

 

 

 

 

 

Income tax benefit (expense)

 

-

 

-

 

-

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS

$

(64,322)

  $

(45,449)

$

(57,590)

$

(244,276)

 

 

 

 

 

 

 

 

 

NET LOSS PER SHARE - BASIC AND DILUTED


$

(0.01)


  $

(0.01)


$

(0.01)


$

(0.01)

 

 

 

 

 

 

 

 

 


WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED


  53,726,967

 

       47,213,634


               53,726,967

 

       47,213,634

 

 






The accompanying notes are an integral part of these condensed consolidated financial statements.



7





REFLECT SCIENTIFIC, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

For the

Nine Months Ended

September 30,

 

 

2014

 

2013

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

Net loss

$

(57,590)

$

(244,276)

Adjustments to reconcile net loss to net cash

 

 

 

 

 from operating activities:

 

 

 

 

  Depreciation

 

1,003

 

6,470

  Amortization

 

29,356

 

29,357

 

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

  (Increase)/decrease in accounts receivable

 

25,321

 

(28,396)

  (Increase)/decrease in inventory

 

15,256

 

36,127

  (Increase)/decrease in prepaid assets

 

-

 

84,000

  Increase/(decrease) in accounts payable

    and accrued expenses

 

70,677

 

50,315

  Increase/(decrease) in customer deposits

 

893

 

-

       Net Cash from Operating Activities

 

84,916

 

(66,403)

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

  Proceeds from lines of credit

 

-

 

4,795

  Payments made on lines of credit

 

(7,594)

 

(27,582)

  Issuance of note payable for cash

 

-

 

20,000

       Net Cash from  Financing Activities

 

(7,594)

 

(2,787)

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH

 

77,322

 

(69,190)

CASH AT BEGINNING OF PERIOD

 

251,463

 

260,575

CASH AT END OF PERIOD

$

328,785

$

191,385



SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

   Cash Paid For:

 

 

 

 

      Interest

$

5,386

$

5,820

      Income taxes

$

-

$

-


The accompanying notes are an integral part of these condensed consolidated financial statements.



8





REFLECT SCIENTIFIC, INC.

Notes to the Condensed Consolidated Financial Statements

(Unaudited)


NOTE 1 -

BASIS OF FINANCIAL STATEMENT PRESENTATION


The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to accounting principles generally accepted in the United States of America. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission.  The information furnished in the interim condensed consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with the Company’s most recent audited consolidated financial statements and notes thereto included in its December 31, 2013 financial statements.  Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.


NOTE 2 -

ORGANIZATION AND DESCRIPTION OF BUSINESS


Cole, Inc. (the Company) was incorporated under the laws of the State of Utah on November 3, 1999. The Company was organized to engage in any lawful activity for which corporations may be organized under the Utah Revised Business Corporation Act.  On December 30, 2003 the Company changed its name to Reflect Scientific, Inc.


NOTE 3 – GOING CONCERN


The Company is currently in default on its issued and outstanding debentures (See note 4).  While the Company is working diligently to secure funding to enable it to retire the debenture obligations, there can be no assurance that such funding will be available.  The Company has also accumulated significant operating losses. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.


Management has taken a number of actions to reduce expenses. Management continues to seek additional funding through the capital markets to facilitate the settlement of the remaining debentures and commercialize its patented detector and refrigeration products, as well as to provide operating capital for its operations.  However, there can be no assurance that additional funding will be available on acceptable terms, if at all.  


NOTE 4 – DEFAULT ON CONVERTIBLE DEBENTURES


At September 30, 2014, the remaining outstanding convertible debentures in default were $650,000, including penalties.  The debentures bear an 18% interest rate.  The Company accrued an additional $29,250 in interest during the quarter ended September 30, 2014.  The total accrued interest on this remaining debenture was $617,625 as of September 30, 2014.  Assuming the debentures were converted, 1,000,000 shares of restricted common stock would be issued.


 



9





NOTE 5 – RELATED PARTY TRANSACTIONS


 

As of September 30, 2014, two sons of the Company’s president had loaned $80,000 in the form of interest bearing notes to the Company.  The notes issued during 2012, with a principal amount of $40,000, bear interest at the rate of 7.75% per annum with the interest paid monthly.  The notes issued during 2013, with a principal amount of $40,000, bear interest at the rate of 6.00% per annum with the interest paid monthly.  All notes are demand notes, with the principal and any unpaid interest payable upon seven days written notice from the note holder.


NOTE 6 – FAIR VALUE OF FINANCIAL INSTRUMENTS


The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, payables and notes payable.  The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.  The carrying amount of the notes payable approximates fair value as the individual borrowings bear interest at rates that approximate market interest rates for similar debt instruments.


NOTE 7 – RECENT ACCOUNTING PRONOUNCEMENTS


In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40) whereby an entity’s management, in connection with preparing financial statements for each annual and interim reporting period, should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued. Management’s evaluation is to be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued.  If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern the entity should disclose information that enables users of the financial statements to understand management’s evaluation of the significance of the conditions or events and of management’s plans to mitigate the conditions or events.  


The standard is effective for annual periods ending after December 15, 2016, and interim periods therein. Early adoption of this amendment is allowed.  We are currently evaluating the date at which we will adopt this standard.  


In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP.  The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services.  ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.


The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods:  (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).  We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.


The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to



10





determine their effects, if any, on its consolidated results of operation, financial position and cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations.


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations


Special Note Regarding Forward-Looking Statements


The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Annual Report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward- looking statements include a wide range of factors that could materially affect future developments and performance, including the following:


Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest; changes in U.S., global or regional economic conditions, changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments; increased competitive pressures, both domestically and internationally, legal and regulatory developments, such as regulatory actions affecting environmental activities, the imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls; adverse weather conditions or natural disasters, such as hurricanes and earthquakes, labor disputes, which may lead to increased costs or disruption of operations.


This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.


Critical Accounting Policies and Estimates


The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited Financial Statements and accompanying notes.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.  The Company believes there have been no significant changes during the three and nine month periods ended September 30, 2014, to the items disclosed as significant accounting policies in management's Notes to the Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.


 




11




Plan of Operation and Business Growth

 

We continue to be focused on increasing the sales of our life science consumables and detectors while also working to commercialize our liquid nitrogen refrigeration products.  Of those liquid nitrogen refrigeration products, the refrigerated trailer, known as a “reefer”, is receiving highest priority.  We continue to test, gather and analyze data generated from road tests of our first manufactured unit to validate its efficiency and reliability.  We have also developed alliances with contract manufacturers for our ultra-low temperature freezers.

 

We continue to develop the market visibility of our detector.  We believe that the enhanced functionality of our detector, coupled with its low cost, provides us with a competitive edge over products currently being sold in that specialized market.


Concurrent with the development and commercialization of the above products, we are working to expand sales of our specialty laboratory supplies and detectors through widening our catalog distribution, our on-line order site, and the addition of new distributors.  While there was a decline in sales in the most recent quarter our year-to-date sales have shown improvement over prior year sales.


Our revenues during the three months ended September 30, 2014 were 25% lower than sales for the same period of the prior year, but year-to-date sales through September 30, 2014 are 12% ahead of 2013 sales for the same period.


Results of Operations


Three Months Ended September 30, 2014 and 2013


 

 

For the three months ended September 30,

 

 

           2014

 

       2013

 

        Change

Revenues

$

290,711

$

389,562

$

(98,851)

Cost of goods sold

 

116,264

 

181,931

 

(65,667)

Gross profit

 

174,447

 

207,631

 

(33,184)

Operating expenses

 

207,917

 

222,621

 

(14,704)

Other income (expense)

 

(30,852)

 

(30,459)

 

(393)

Net loss

$

(64,322)

$

(45,449)

   $

(18,873)


Revenues of $290,711 for the quarter ended September 30, 2014 were $98,851 lower than the $389,562 for the quarter ended September 30, 2013.  We believe the final three months of 2014 will yield sales results more in line with those during the first half of 2014.  All of the revenues generated during the three month period ended September 30, 2014 were from our specialized laboratory supplies and detector sales.


With sales during the reporting period running at a lower level, cost of goods also decreased in the quarter ending September 30, 2014, as compared to September 30, 2013 to $116,264 from $181,931, a decrease of $65,667. The gross profit percentage increased to 60% for the three months ended September 30, 2014, compared to 53% for the three months ended September 30, 2013.  The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter.  We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on our product lines.  


As a result of our continued focus on operating expenses we realized a further reduction of operating expenses in the current period.  This reduction is the result of cost reduction efforts implemented by management and an ongoing quest to gain additional operating efficiencies.  Operating expenses for the three months ended September 30, 2014 were $207,917, which represents a decrease of $14,704 from the



12





$222,621 in operating expenses recorded for the three month period ended September 30, 2013.  The decrease is primarily the result of reduced consulting expense, offset in part by increases in personnel expenses and research and development costs.  Operating expenses for the remaining three months of 2014 are expected to approximate the expense levels shown for the three month period ended September 30, 2014.


The net loss for the three month period ended September 30, 2014 was $64,322, an increase of $18,873 over the $45,449 loss for the three month period ended September 30, 2013.  Management continues to look for opportunities to increase sales, improve gross margins and reduce ongoing operating expenses.


The net loss for both of the three months ended September 30, 2014 and September 30, 2013 was $0.01 per share.  


Nine Months Ended September 30, 2014 and 2013


 

 

For the nine months ended September 30,

 

 

          2014

 

       2013

 

        Change

Revenues

$

1,072,066

$

954,527

$

117,539

Cost of goods sold

 

447,513

 

448,923

 

(1,410)

Gross profit

 

624,553

 

505,604

 

118,949

Operating expenses

 

589,971

 

665,940

 

(75,969)

Other income (expense)

 

(92,172)

 

(83,940)

 

(8,232)

Net loss

$

(57,590)

$

(244,276)

$

186,686


Revenues during the nine month period ended September 30, 2014 were $1,072,066, an increase of $117,539 from the $954,527 revenue for the nine months ended September 30, 2013.  All of the revenues were generated from our specialized laboratory supplies and detector sales.  We completed our catalog web site and have distributed our catalog to a number of potential new distributors.  We have brought on additional distributors to expand the distribution channels for our products.  


Despite an increase in sales, our cost of goods sold in the nine month period ending September 30, 2014 decreased by $1,410, to $447,513 from $448,923 for the nine month period ended September 30, 2013. The gross profit percentage increased to 58% for the nine month period ended September 30, 2014, compared to 53% for the nine months ended September 30, 2013.  The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter.  We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on our product lines.  


Continued focus to reduce operating expenses resulted in a reduction of $75,969 in the current nine month period.  This reduction is the result of cost reduction efforts implemented by management and an ongoing quest to gain additional operating efficiencies.  Operating expenses for the nine months ended September 30, 2014 were $589,971, compared to $665,940 shown for the nine month period ended September 30, 2013.


Net loss for the nine month period ended September 30, 2014 was $57,590, an $186,686 improvement from the $244,276 net loss for the nine month period ended September 30, 2013.  Management continues to look for opportunities to increase revenue, improve gross margins and reduce ongoing operating expenses in order to achieve profitability.


Loss per share for the nine months ended September 30, 2014 was $0.01 per share.  The net loss for the

nine months ended September 30, 2013 was also $0.01 per share.

13





Seasonality and Cyclicality


We do not believe our business is cyclical.


Liquidity and Capital Resources


Our cash resources at September 30, 2014, were $328,785, with accounts receivable of $127,262 and inventory of $297,837. Up to this time we have relied on revenues and sales of equity and debt securities for our cash resources.   Our working capital deficit on September 30, 2014, was $664,100, due primarily to the $650,000 in outstanding debentures and $617,625 in accrued interest on those debentures.  Working capital on December 31, 2013 was a deficit of $636,869.  Management is working to obtain financing to enable it to retire the remaining outstanding debentures and provide the capital needed to commercialize the low temperature freezer and refrigeration technology.  There can be no assurance that funds will be available, or that terms of available funds will be acceptable to the Company.  The inability of the Company to obtain funding at acceptable terms could negatively impact its ability to execute its business plan.


For the nine month period ended September 30, 2014, net cash provided from operating activities was $84,916 which compares to $66,403 net cash used for operating activities for the nine month period ended September 30, 2013.  


Off-Balance Sheet Arrangements


We lease office and warehouse space under a non-cancelable operating lease in Utah.  We recently entered into an extension of our office and warehouse lease which will terminate November 30, 2017. Future minimum lease payments under the operating lease at September 30, 2014 are $117,800 for that facility, with minimum lease payments under the lease of $9,300 for the remainder of 2014, $37,200 per year for 2015 and 2016 and $34,100 in 2017.  In addition, on May 9, 2014, the Company entered into an automobile lease. Future minimum lease payments under this lease are $21,216 at September 30, 2014, with minimum lease payments of $1,872 due for the remainder of 2014, $7,488 in 2015, $7,488 in 2016, and $4,368 in 2017.




14





Item 3.  Quantitative and Qualitative Disclosure about Market Risk


Not required.


Item 4.  Controls and Procedures


(a)

Evaluation of Disclosure Controls and Procedures.


As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures.  Based upon this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods, and is accumulated and communicated to management, including our Chief Executive Officer and Principal Financial Officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports.  Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures are effective.  It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote


(b)

Changes in Internal Control Over Financial Reporting.


During the fourth quarter of 2013, we identified certain impairment indicators that led us to perform procedures to assess the possible impairment of our goodwill. While we correctly identified these impairment indicators, we did not have adequate procedures and controls in place to ensure that the requisite analysis to determine the amount of impairment could be conducted in a timely, accurate and complete manner.  During the nine months ended September 30, 2014 we have been implementing enhanced documentation, review and supervision processes and procedures over impairment-related testing and analysis.  Those changes are now fully implemented and their implementation provides reasonable assurance that the quality and frequency of impairment testing is being properly monitored.  However, it should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

 

PART II - OTHER INFORMATION


ITEM 1.  Legal Proceedings


None; not applicable.


ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds


Recent Sales of Unregistered Securities


None; not applicable.


Use of Proceeds of Registered Securities


None; not applicable.

15






 


Purchases of Equity Securities by Us and Affiliated Purchasers


During the nine months ended September 30, 2014, we have not purchased any equity securities nor have any officers or directors of the Company.


ITEM 3.  Defaults Upon Senior Securities


At September 30, 2014, the remaining outstanding convertible debentures in default were $650,000, including penalties.  The debentures bear an 18% interest rate.  The Company accrued an additional $29,250 in interest during the quarter ended September 30, 2014.  The total accrued interest on this remaining debenture was $617,625 as of September 30, 2014.  Assuming the debentures were converted, 1,000,000 shares of restricted common stock would be issued.


ITEM 4.  Mine Safety Disclosure


Not applicable.


ITEM 5.  Other Information.


None




16





ITEM 6.  Exhibits


(a)

Exhibits.


 

 

 

Exhibit No.

Title of Document

Location if other than attached hereto

3.1

Articles of Incorporation

10-SB Registration Statement*

3.2

Articles of Amendment to Articles of Incorporation

10-SB Registration Statement*

3.3

By-Laws

10-SB Registration Statement*

3.4

Articles of Amendment to Articles of Incorporation

8-K Current Report dated December 31, 2003*

3.5

Articles of Amendment to Articles of Incorporation

8-K Current Report dated December 31, 2003*

3.6

Articles of Amendment

September 30, 2004 10-QSB Quarterly Report*

3.7

By-Laws Amendment

September 30, 2004 10-QSB Quarterly Report*

4.1

Debenture

8-K Current Report dated June 29, 2007*

4.2

Form of Purchasers Warrant

8-K Current Report dated June 29, 2007*

4.3

Registration Rights Agreement

8-K Current Report dated June 29, 2007*

4.4

Form of Placement Agreement

8-K Current Report dated June 29, 2007*

10.1

Securities Purchase Agreement

8-K Current Report dated June 29, 2007*

10.2

Placement Agent Agreement

8-K Current Report dated June 29, 2007*

14

Code of Ethics

December 31, 2003 10-KSB Annual Report*

21

Subsidiaries of the Company

December 31, 2004 10-KSB Annual Report*

31.1

302 Certification of Kim Boyce

 

31.2

302 Certification of Keith Merrell

 

32

906 Certification

 


Exhibits


Additional Exhibits Incorporated by Reference

 

 

 

*

Reflect California Reorganization

8-K Current Report dated December 31, 2003

*

JMST Acquisition

8-K Current Report dated April 4, 2006

*

Cryomastor Reorganization

8-K Current Report dated September 27, 2006

*

Image Labs Merger Agreement Signing

8-K Current Report dated November 15, 2006

*

All Temp Merger Agreement Signing

8-K Current Report dated November 17, 2006

*

All Temp Merger Agreement Closing

8-KA Current Report dated November 17, 2006

*

Image Labs Merger Agreement Closing

8-KA Current Report dated November 15, 2006

* Previously filed and incorporated by reference.



17





SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Reflect Scientific, Inc.

(Registrant)


Date:

November 10, 2014

By:  /s/ Kim Boyce

       Kim Boyce, CEO, President and Director


Date:

November 10, 2014

By:  /s/ Tom Tait

        Tom Tait, Vice President and Director


Date:

November 10, 2014

By:  /s/ Keith Merrell

        Keith Merrell, CFO, Principal Financial

Officer





18